Navigation Links
Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
Date:4/9/2009

SUNNYVALE, Calif., April 9 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that it will report financial results for its fiscal first quarter ended March 31, 2009, on Thursday, April 23, 2009, after the close of the market.

The company will host a management presentation at 2 p.m. Pacific Time on Thursday, April 23, 2009, to discuss the results. To access the live webcast, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.

Interested participants and investors may also listen to the live teleconference call by dialing (866) 700-6067 (domestic) or (617) 213-8834 (international), and entering participant code 21782083. A replay will be available for seven days beginning at 4 p.m. Pacific Time. Access numbers for this replay are (888) 286-8010 (domestic) and (617) 801-6888 (international), with participant code 78028998.

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The Company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the Company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market.

    CONTACTS:
    For Media Inquiries:                 For Investor Inquiries:
    Jared Tipton                         Jacquie Ross
    Cepheid Corporate                    Cepheid Investor
    Communications                       Relations
    Tel: (408) 400 8377                  Tel: (408) 400 8329
    jared.tipton@cepheid.com             investor.relations@cepheid.com


'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
2. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
3. Cepheid to Webcast Upcoming Financial Presentations
4. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
5. Cepheid Reports Third Quarter Revenue of $44.9 Million
6. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
7. Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized Moderate Complexity by FDA
8. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
9. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
10. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
11. Cepheid to Webcast Upcoming Financial Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017  In Atlanta, it seems everyone has ... culture intertwine to create an expressive and dynamic community unlike ... energy and contribute to it. With their ... Fairies seeks to carry on that tradition with a ... Atlanta salon is the newest of 13 nationwide ...
(Date:2/23/2017)... ... February 23, 2017 , ... David ... Inventors Recognition Reception at Purdue Research Park of West Lafayette, Indiana. ... recognition of outstanding contributions to, and success with, commercializing discoveries from Purdue research. ...
(Date:2/23/2017)... SAN FRANCISCO , Feb. 23, 2017   ... Beyond Type 1, a not-for-profit advocacy and education group ... a grant from Beyond Type 1 to support ViaCyte,s ... and other insulin-requiring diabetes.  For more ... cell-derived cell replacement therapies with a focus on the ...
(Date:2/22/2017)... , Feb. 22, 2017  PrimeVax Immuno-Oncology, Inc. announced ... presenting at the Annual Biocom Global Life Science Partnering ... at 11:15 AM, at the Torrey Pines Lodge, in ... the organizers at Biocom who have chosen our company, ... of biotechnology companies, investors, and clinical researchers," said Mr. ...
Breaking Biology Technology:
(Date:1/24/2017)... 24, 2017  It sounds simple and harmless—an ... monitors vital signs and alerts parents on their ... saturation level drops. But pediatric experts argue that ... with no evidence of medical benefits, especially to ... aggressively to parents of healthy babies, promising peace ...
(Date:1/19/2017)... India , January 19, 2017 According to a ... Opportunities and Forecast, 2014 - 2022," the global biometric sensor market is expected ... 2016 to 2022. In 2015, Asia-Pacific dominated the global ... and private sectors. Continue Reading ... ...
(Date:1/18/2017)... Jan. 18, 2017 MedNet Solutions ... supports the entire spectrum of clinical research, is ... record-breaking year for the organization in terms of ... MedNet,s eClinical products and services. The company,s exceptional ... success of iMedNet ™ ...
Breaking Biology News(10 mins):